knowledge -WSS

knowledge

author：focus 2025-09-30 00:45:10 - browse：435

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Monday approved a gene therapy for metachromatic leukodystrophy, a devastating genetic disorder that eats away at affected children’s neurons.

The medicine, marketed as Lenmeldy, is the first treatment for MLD, which is otherwise fatal. Lenmeldy has to be given before symptoms appear or, in some cases, after the first signs of disease, so it won’t be helpful for many patients living with MLD today. But when given in time, it appears to be near-curative, allowing some children to grow up and attend school with unaffected peers.

Lenmeldy is already marketed in Europe, under the name Libmeldy, and has helped a handful of patients in the U.S. who were treated under compassionate use, as their doctors feared they didn’t have time to wait for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Unicorn down: Following layoffs, Biofourmis CEO quietly departs

WSS

Grail spinoff by Illumina should end disastrous merger attempt

SNAP should offer more nutrition education

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Keeping primary care docs in field isn't impossible, says AAFP CEO

Bristol Myers buys into radiopharmaceuticals with RayzeBio

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Wikipedia

knowledge

knowledge

The high cost of giving birth even with insurance

CDC advisory panel says seniors 'may' get RSV vaccine

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

How to make AI work for medicine

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

What AAP's gender

Duchenne breakthrough therapy leaves behind pioneering families

What STAT readers think about the FDA and patient advocacy

In Memoriam: Notable people who died in 2023

Grail spinoff by Illumina should end disastrous merger attempt

Wikipedia

Why more medical students aren't specializing in primary care

AstraZeneca bets AAV gene therapy will still deliver the goods

Radiation, mainstay of cancer treatment, begins a fade

Radiation, mainstay of cancer treatment, begins a fade

Why more medical students aren't specializing in primary care

2024 GOP presidential candidates spar over abortion in debate

hotspot

hotspot

entertainment

hotspot